Prostaglandin Procedures

  • Marc A. Bygdeman


Although effective contraceptive methods are available, induced abortion remains important as a means of fertility control all over the world. Considerable efforts have been devoted to the study of and improvements in abortion technology. Further refinements are still possible, however, in terms of greater effectiveness, diminished complications, enhanced technical ease, greater convenience, and lower costs. This is particularly true for second-trimester procedures, where the techniques currently in use result in significantly higher maternal morbidity and mortality compared to first-trimester abortions. For many years the most widely used method for terminating pregnancy in the second trimester has been the intraamniotic administration of hypertonic saline. More recently, however, intraamniotic prostaglandins have been used with increasing frequency and considerable success. At present, the use of PGF has been approved by drug safety regulating authorities in approximately 50 countries.


Obstet Gynecol Hypertonic Saline Gastrointestinal Side Effect Prostaglandin Analogue Trimester Pregnancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Embrey MP, Hillier K, Mahendran P: Termination of pregnancy by extra-amniotic prostaglandins and the synergistic effect of oxytocin. Adv Bio-sciences 9:507, 1973.Google Scholar
  2. 2.
    Bygdeman M, Beguin F, Toppozada M, et al: Intrauterine administration of prostaglandin F for induction of abortion. Adv Biosciences 9:525, 1973.Google Scholar
  3. 3.
    Lauersen NH, Wilson KH: Continuous extraovular administration of prostaglandin F for midtrimester abortions. Am J Obstet Gynecol. 120:273, 1974.PubMedGoogle Scholar
  4. 4.
    Lange AP, Secher NJ, Thomsen-Pedersen G: Induction of therapeutic abortion using either extra-amniotic prostaglandin F or hypertonic saline followed by oxytocin. Prostaglandins 6:149, 1974.PubMedCrossRefGoogle Scholar
  5. 5.
    Bygdeman M: Comparison of prostaglandin and hypertonic saline for termination of pregnancy. Obstet Gynecol. 52:424, 1978.PubMedGoogle Scholar
  6. 6.
    Mackenzie IZ, Hillier K, Embrey MP: Single extra-amniotic injection of prostaglandin E2 in viscous gel to induce midtrimester abortion. Br Med J 1:240, 1975.PubMedCrossRefGoogle Scholar
  7. 7.
    WHO Prostaglandin Task Force: Single extraamniotic administration of 0.92 mg 15-methyl PGF in hyscon for termination of pregnancy in the 10th to 20th week of gestation. An international multicentre study. Am J Obstet Gynecol. 129:597, 1977.Google Scholar
  8. 8.
    Karim SMM: Singapore experience with prostaglandin. Routine use and recent advances, in Obstetrical and Gynecological Uses of Prostaglandin, vol 1. Lancaster, England, MTP, 1976, p 127.Google Scholar
  9. 9.
    Karim SMM, Ratnam SS: Newer aspects of practical applications of prostaglandins in obstetrics and gynecology, in Kharasch N, Fried J (eds): Biochemical Aspects of Prostaglandins and Thromboxanes. New York, Academic Press, 1977.Google Scholar
  10. 10.
    Corson SL, Bolognese RJ: Use of intramuscular 15(S), 15-methyl prostaglandin F in failed abortions. Am J Obstet Gynecol. 133:145, 1979.PubMedGoogle Scholar
  11. 11.
    Lauersen NH, Wilson KH: The effects of intra-muscular injections of 15(S), 15-methyl prostaglandin F in failed abortion. Fertil Steril 28:381, 1977.Google Scholar
  12. 12.
    Anderson GG, Steege J: Clinical experience using intra-amniotic prostaglandin F for midtrimester abortion in 600 patients. Obstet Gynecol. 46:591, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Kajanoja P, Jungner G, Seppala M, et al: Prostaglandin induction of 424 midtrimester abortions. Int J Gynaecol. Obstet 12:198, 1974.PubMedGoogle Scholar
  14. 14.
    WHO Prostaglandin Task Force: Comparison of intraamniotic prostaglandin F and hypertonic saline for induction of second trimester abortion. Br Med J. 1:1370, 1976.Google Scholar
  15. 15.
    WHO Prostaglandin Task Force: Comparison of single intraamniotic injections of 15-methyl prostaglandin F and PGF for termination of second trimester pregnancy. An international multicentre study. Am J Obstet Gynecol. 129:601, 1977.Google Scholar
  16. 16.
    Edelman DA, Brenner WE, Mehta AC, et al: A comparative study of intra-amniotic saline and two prostaglandin F dose schedules for midtrimester abortion. Am J Obstet Gynecol. 125:188, 1976.PubMedGoogle Scholar
  17. 17.
    Toppozada M, Beguin F, Bygdeman M, et al: Response of the midpreg-nant human uterus to systemic administration of 15(S), 15-methyl prostaglandin F. Prostaglandins 2:239, 1972.PubMedCrossRefGoogle Scholar
  18. 18.
    Green K, Granstrom E, Bygdeman M, et al: Kinetic and metabolic studies of 15-methyl prostaglandin F administered intra-amniotically for induction of abortion. Prostaglandins 11:699, 1976.PubMedCrossRefGoogle Scholar
  19. 19.
    WHO Prostaglandin Task Force: Intramuscular administration of 15-methyl PGF for induction of abortion in the 10th to 20th week of pregnancy. Am J Obstet Gynecol. 129:593, 1977.Google Scholar
  20. 20.
    Karim SMM, Choo HT, Lim AL, et al: Termination of second trimester pregnancy with intramuscular administration of 16-phenoxy w 17,18,19,20-tetranor PGE2 methyl-sulphonylamide. Prostaglandins 15:1063, 1978.PubMedCrossRefGoogle Scholar
  21. 21.
    Brenner WE, Gruber W, Staurovsky LG, et al: Induction of artificial abortion with intramuscular administration of 15(S), 15-methyl PGE2 and 15(S), 15-methyl PGF, in Obstetrical and Gynecological Uses of Prostaglandins, vol 1. Lancaster, England, MTP, 1976, p 175.Google Scholar
  22. 22.
    Green K, Bygdeman M, Leader A, et al: Pharmacokinetic studies on 15-methyl prostaglandin F and its methylester after administration to the human via various routes for induction of abortion, in Advances in Prostaglandin and Thromboxane Research, vol 2. New York, Raven Press, 1976, p 719.Google Scholar
  23. 23.
    Green K, Bygdeman M: Plasma levels of 15(S), 15-methyl PGF following administration in various routes for induction of abortion. Prostaglandins 14:1013, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Bygdeman M, Borell U, Leader A, et al: Induction of first and second trimester abortion by the vaginal administration, in Advances in Prostaglandin and Thromboxane Research, vol 2. New York, Raven Press, 1976, p 693.Google Scholar
  25. 25.
    Bygdeman M, Ganguli A, Kinoshita K, et al: Development of vaginal suppository suitable for single administration of interruption of second trimester pregnancy. Contraception 15:129, 1977.PubMedCrossRefGoogle Scholar
  26. 26.
    Martin JN, Bygdeman M, Ramadan M, et al: Vaginally administered 16,16-dimethyl PGE2 for the induction of midtrimester abortion. Prostaglandins 11:123, 1976.PubMedCrossRefGoogle Scholar
  27. 27.
    Bygdeman M, Green K, Bergstrom S, et al: New prostaglandin E2 analogue for pregnancy termination. Lancet 1:1136, 1979.PubMedCrossRefGoogle Scholar
  28. 28.
    Edelman DA, Brenner WE, Berger GS: The effectiveness and complications of abortions by dilatation and vacuum aspiration versus dilatation and rigid metal curettage. Am J Obstet Gynecol. 119:473, 1974.PubMedGoogle Scholar
  29. 29.
    Grimes DA, Schultz KF, Cates W, et al: Midtrimester abortion by dilatation and evacuation: A safe and practical alternative. N Engl J Med. 296:1141, 1977.PubMedCrossRefGoogle Scholar
  30. 30.
    Frankman O, Bygdeman M, Green K, et al: Dilatation of the cervix prior to vacuum aspiration by single vaginal administration of 15-methyl PGF methyl ester. Contraception 21:571, 1980.PubMedCrossRefGoogle Scholar
  31. 31.
    Brenner WE, Berger GS: Pharmacologic methods of inducing mid-trimester abortion: Risks and benefits, in Sciarra J, Zatuchni GI, Speidel JJ (eds): Risks, Benefits, and Controversies in Fertility Control. Hagerstown, Md., Harper & Row, 1978.Google Scholar
  32. 32.
    Kajanoja P, Jungner G, Widholm O, et al: Rupture of the cervix in prostaglandin abortion.J Obstet Gynaecol. Br Commonw. 81:242, 1974.PubMedCrossRefGoogle Scholar
  33. 33.
    Grimes DA, Schulz KF, Cates W, et al: Midtrimester abortion by intra-amniotic prostaglandin F. Safer than saline? Obstet Gynecol. 49:612, 1977.PubMedGoogle Scholar
  34. 34.
    Cates W, Grimes DA, Haber RH, et al: Abortion deaths associated with the use of prostaglandin F. Am J Obstet Gynecol. 127:219, 1977.PubMedGoogle Scholar

Copyright information

© Gary S. Berger, William E. Brenner and Loius G. Keith 1981

Authors and Affiliations

  • Marc A. Bygdeman

There are no affiliations available

Personalised recommendations